ClinicalTrialsFinder
RecruitingPhase 2NCT07220603

An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

Sponsor

PepGen Inc

Enrollment

48 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Myotonic Dystrophy 1

Summary

The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PGN-EDODM1 for people with myotonic dystrophy 1. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPGN-EDODM1

Administered by intravenous (IV) infusion

Locations(3)

University of Calgary

Calgary, Alberta, Canada

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

CIUSSS du Saguenay-Lac-Saint-Jean

Saguenay, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07220603

Related Trials

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

NCT077002251 location

Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy

NCT0613874311 locations

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

NCT066674538 locations

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

NCT0398157517 locations

Study of ATX-01 in Participants With DM1

NCT0630030712 locations